Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Feb 16;30(1):1-2.
doi: 10.1016/j.joco.2018.01.006. eCollection 2018 Mar.

Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation

Hossein Ameri  1
Affiliations
Editorial

Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation

Hossein Ameri. J Curr Ophthalmol. .
No abstract available

PubMed Disclaimer

References

    1. Morimura H., Fishman G.A., Grover S.A., Fulton A.B., Berson E.L., Dryja T.P. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc Natl Acad Sci U S A. 1998;95(6):3088–3093. - PMC - PubMed
    1. Gu S.M., Thompson D.A., Srikumari C.R. Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet. 1997;17(2):194–197. - PubMed
    1. Marlhens F., Bareil C., Griffoin J.M. Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet. 1997;17(2):139–141. - PubMed
    1. Acland G.M., Aguirre G.D., Ray J. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28(1):92–95. - PubMed
    1. Maguire A.M., High K.A., Auricchio A. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374(9701):1597–1605. - PMC - PubMed

Publication types